JPWO2020247820A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020247820A5 JPWO2020247820A5 JP2021572418A JP2021572418A JPWO2020247820A5 JP WO2020247820 A5 JPWO2020247820 A5 JP WO2020247820A5 JP 2021572418 A JP2021572418 A JP 2021572418A JP 2021572418 A JP2021572418 A JP 2021572418A JP WO2020247820 A5 JPWO2020247820 A5 JP WO2020247820A5
- Authority
- JP
- Japan
- Prior art keywords
- drug
- human
- sirpα
- assay
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Claims (8)
(a)薬物に結合し、かつ前記試薬RBCまたは前記試薬血小板の薬物の結合をブロックする薬物中和剤を、前記薬物による治療を受けた対象由来の血漿試料へ添加することと、
(b)前記試薬RBCまたは前記試薬血小板を使用して、ステップ(a)の後に前記血漿試料の前記血清学的アッセイを実行することと、を含み、
前記薬物は、(i)ヒト抗体Fc領域、及び(ii)ヒトCD47に結合する部分を含み、
ヒトCD47に結合する前記薬物の部分が、
(1)膜貫通ドメインを欠く野生型SIRPα、または
(2)野生型SIRPαの細胞外ドメインと比較して、1つ以上のアミノ酸置換(複数可)、欠失(複数可)、挿入(複数可)、N末端付加(複数可)及び/またはC末端付加(複数可)を含み、ヒトCD47に結合することができ、かつ膜貫通ドメインを欠く、SIRPαバリアント
を含み、
前記薬物中和剤が、抗SIRPα抗体であるか、またはヒトCD47に結合する前記部分に結合することができるその抗原結合フラグメントである、前記方法。 1. A method of reducing drug interference in a pre-transfusion serological assay using reagent red blood cells (RBCs) or reagent platelets, comprising:
(a) adding to a plasma sample from a subject treated with the drug a drug-neutralizing agent that binds the drug and blocks binding of the drug to the reagent RBCs or the reagent platelets;
(b) performing said serological assay of said plasma sample after step (a) using said reagent RBCs or said reagent platelets;
said drug comprises (i) a human antibody Fc region and (ii) a portion that binds to human CD47 ;
the portion of the drug that binds to human CD47
(1) wild-type SIRPα lacking a transmembrane domain, or
(2) one or more amino acid substitution(s), deletion(s), insertion(s), N-terminal addition(s) and/or C compared to the extracellular domain of wild-type SIRPα A SIRPα variant comprising terminal addition(s), capable of binding human CD47, and lacking a transmembrane domain
including
The above method, wherein the drug-neutralizing agent is an anti-SIRPα antibody or an antigen-binding fragment thereof capable of binding to the portion that binds to human CD47.
(a)薬物による治療を受けた対象の由来の前記血液試料に、抗SIRPα抗体またはその抗原結合フラグメントを追加することと、 (a) adding an anti-SIRPα antibody or antigen-binding fragment thereof to said blood sample from a subject who has been treated with a drug;
(b)ステップ(a)の後に、試薬血漿/抗血清を使用した前記血液試料の前記血清学的アッセイを実行することと (b) after step (a), performing said serological assay of said blood sample using reagent plasma/antiserum;
を含み、including
前記薬物は、(i)ヒト抗体Fc領域、及び(ii)ヒトCD47に結合する野生型SIRPαまたはそのバリアントの細胞外ドメインを含み、SIRPαバリアントは、野生型SIRPαの細胞外ドメインと比較して、1つ以上のアミノ酸置換(複数可)、欠失(複数可)、挿入(複数可)、N末端付加(複数可)及び/またはC末端付加(複数可)を含み、ヒトCD47に結合することができ、かつ膜貫通ドメインを欠き、 The drug comprises (i) a human antibody Fc region, and (ii) an extracellular domain of wild-type SIRPα or a variant thereof that binds to human CD47, wherein the SIRPα variant, compared to the extracellular domain of wild-type SIRPα, comprising one or more amino acid substitution(s), deletion(s), insertion(s), N-terminal addition(s) and/or C-terminal addition(s) and binding to human CD47 and lacks a transmembrane domain,
抗SIRPα抗体またはその抗原結合フラグメントは、血液試料中のRBCの表面でCD47に結合した薬物を置換する、前記方法。 The above method, wherein the anti-SIRPα antibody or antigen-binding fragment thereof displaces drug bound to CD47 on the surface of RBCs in the blood sample.
(a)配列番号6を含む重鎖可変ドメイン(V (a) a heavy chain variable domain comprising SEQ ID NO:6 (V HH. )と、配列番号7を含む軽鎖可変ドメイン(V) and a light chain variable domain comprising SEQ ID NO: 7 (V LL. ))
(b)配列番号21を含む重鎖可変ドメイン(V (b) a heavy chain variable domain comprising SEQ ID NO:21 (V HH. )と、配列番号22を含む軽鎖可変ドメイン(V) and a light chain variable domain comprising SEQ ID NO: 22 (V LL. ))
(c)配列番号21を含む重鎖可変ドメイン(V (c) a heavy chain variable domain comprising SEQ ID NO:21 (V HH. )と、配列番号22を含む軽鎖可変ドメイン(V) and a light chain variable domain comprising SEQ ID NO: 22 (V LL. ))
を含む、請求項1または2に記載の方法。3. The method of claim 1 or 2, comprising:
即時スピン(IS)アッセイ
IgG及び補体C3を検出する多重特異性試薬を使用する直接抗グロブリン(DAT)アッセイ、
補体C3を検出する単一特異性試薬を使用する直接抗グロブリン(DAT)アッセイ、
PEG増強血清学的アッセイ、及び/または
前記DATアッセイの後に実施される溶出液試験
である、請求項1~7のいずれか1項に記載の方法。 wherein the pre-transfusion serological assay is an ABO/Rh determination assay ;
Immediate spin (IS) assay
a direct antiglobulin (DAT) assay using multispecific reagents that detect IgG and complement C3;
a direct antiglobulin (DAT) assay using a monospecific reagent that detects complement C3;
PEG-enhanced serological assays, and/or
Eluate test performed after the DAT assay
The method according to any one of claims 1 to 7 , wherein
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962858871P | 2019-06-07 | 2019-06-07 | |
US62/858,871 | 2019-06-07 | ||
US201962934395P | 2019-11-12 | 2019-11-12 | |
US62/934,395 | 2019-11-12 | ||
PCT/US2020/036425 WO2020247820A1 (en) | 2019-06-07 | 2020-06-05 | Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022535286A JP2022535286A (en) | 2022-08-05 |
JPWO2020247820A5 true JPWO2020247820A5 (en) | 2023-06-13 |
Family
ID=71899853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021572418A Pending JP2022535286A (en) | 2019-06-07 | 2020-06-05 | Methods and reagents for reducing interference of drugs that bind CD47 in serological assays |
Country Status (6)
Country | Link |
---|---|
US (1) | US20200400662A1 (en) |
EP (1) | EP3980747A1 (en) |
JP (1) | JP2022535286A (en) |
CN (1) | CN114206912A (en) |
MA (1) | MA56119A (en) |
WO (1) | WO2020247820A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3331902T3 (en) | 2015-08-07 | 2021-07-26 | Alx Oncology Inc | CONSTRUCTIONS WITH A SIRP ALPHA DOMAIN OR VARIANT THEREOF |
US11613564B2 (en) | 2019-05-31 | 2023-03-28 | ALX Oncology Inc. | Methods of treating cancer |
CN116261662B (en) * | 2020-10-14 | 2024-05-31 | 天境生物科技(上海)有限公司 | Methods for reducing interference of therapeutic anti-CD 47 antibodies in pre-transfusion assays |
WO2024105180A1 (en) | 2022-11-16 | 2024-05-23 | Boehringer Ingelheim International Gmbh | Predictive efficacy biomarkers for anti-sirpa antibodies |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
KR20120107122A (en) | 2009-12-22 | 2012-09-28 | 노파르티스 아게 | Tetravalent cd47-antibody constant region fusion protein for use in therapy |
MX2013014789A (en) | 2011-06-16 | 2014-01-20 | Novartis Ag | Soluble proteins for use as therapeutics. |
DK2804617T3 (en) | 2012-01-17 | 2020-08-10 | Univ Leland Stanford Junior | High affinity sirp alpha reagents |
US20140140989A1 (en) | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
NZ628314A (en) | 2012-02-06 | 2017-01-27 | Inhibrx Lp | Cd47 antibodies and methods of use thereof |
JP6392770B2 (en) | 2012-12-03 | 2018-09-19 | ノビミューン エスアー | Anti-CD47 antibody and method of use thereof |
SG11201504469XA (en) | 2012-12-12 | 2015-07-30 | Vasculox Inc | Therapeutic cd47 antibodies |
US9221908B2 (en) | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
PT3575326T (en) | 2012-12-17 | 2022-05-30 | Pf Argentum Ip Holdings Llc | Treatment of cd47+ disease cells with sirp alpha-fc fusions |
SG11201506132PA (en) | 2013-02-06 | 2015-09-29 | Inhibrx Llc | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
CN106535914B (en) | 2014-08-08 | 2021-08-27 | Alx 肿瘤生物技术公司 | SIRP-alpha variant constructs and uses thereof |
EP3012271A1 (en) | 2014-10-24 | 2016-04-27 | Effimune | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
WO2016081423A1 (en) | 2014-11-18 | 2016-05-26 | Janssen Pharmaceutica Nv | Cd47 antibodies, methods, and uses |
JP6850255B2 (en) | 2014-12-30 | 2021-03-31 | セルジーン コーポレイション | Anti-CD47 antibody and its use |
PT3277821T (en) | 2015-03-31 | 2019-10-31 | Novimmune Sa | Method for optimizing the assembly and production of hetero-multimeric protein complexes |
CN106146670B (en) | 2015-04-24 | 2019-01-15 | 宜明昂科生物医药技术(上海)有限公司 | A kind of new recombination double functions fusion protein and its preparation and application |
WO2016179399A1 (en) | 2015-05-06 | 2016-11-10 | The Board Of Trustees Of The Leland Stanford Junior University | High affinity cd47 analogs |
WO2016187226A1 (en) | 2015-05-18 | 2016-11-24 | Ab Initio Biotherapeutics, Inc. | Sirp polypeptide compositions and methods of use |
DK3331902T3 (en) | 2015-08-07 | 2021-07-26 | Alx Oncology Inc | CONSTRUCTIONS WITH A SIRP ALPHA DOMAIN OR VARIANT THEREOF |
JP6885606B2 (en) | 2015-09-18 | 2021-06-16 | アーチ オンコロジー, インコーポレイテッドArch Oncology, Inc. | Therapeutic CD47 antibody |
JP2018535692A (en) | 2015-09-21 | 2018-12-06 | エラスムス ユニバーシティ メディカル センターErasmus University Medical Center | Anti-CD47 antibody and method of use |
US20180312600A1 (en) | 2015-10-21 | 2018-11-01 | Ose Immunotherapeutics | Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer |
BR112018014028A2 (en) | 2016-01-11 | 2019-02-05 | Forty Seven Inc | humanized, mouse or chimeric anti-cd47 monoclonal antibodies |
BR112018070823A2 (en) | 2016-04-14 | 2019-02-05 | Ose Immunotherapeutics | anti-human sirpa antibody or antigen-binding fragment thereof or antigen-binding antibody mimetic, pharmaceutical composition, combination product, isolated nucleic acid molecule, vector, isolated host cell, polypeptide, methods for making an antibody, in in vitro or ex vivo to determine sirp positive, diagnostic and predictive response cells of a subject, and use of an anti-sirp antibody or antigen-binding fragment thereof or an antibody-binding mimetic in vitro or ex vivo of at least one anti-human sirpa antibody or antigen binding fragment thereof or antigen binding antibody mimetic. |
US20190091290A1 (en) | 2016-04-15 | 2019-03-28 | Trillium Therapeutics Inc. | Macrophage stimulation in cd47 blockade therapy |
JP2019518742A (en) | 2016-05-09 | 2019-07-04 | セルジーン コーポレーションCelgene Corporation | CD47 antibody and method of using the same |
MX2019000172A (en) | 2016-07-06 | 2019-09-26 | Celgene Corp | Antibodies with low immunogenicity and uses thereof. |
CA3031034A1 (en) | 2016-08-03 | 2018-02-08 | The Board Of Trustees Of The Leland Stanford Junior University | Disrupting fc receptor engagement on macrophages enhances efficacy of anti-sirpalpha antibody therapy |
JOP20190009A1 (en) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | Antibodies against signal-regulatory protein alpha and methods of use |
CN108738313B (en) | 2016-10-20 | 2022-12-30 | 天境生物科技(上海)有限公司 | Novel CD47 monoclonal antibody and application thereof |
EP3529276A4 (en) | 2016-10-21 | 2020-06-17 | Arch Oncology, Inc. | Therapeutic cd47 antibodies |
EP3534964A4 (en) | 2016-11-03 | 2020-07-15 | Trillium Therapeutics Inc. | Enhancement of cd47 blockade therapy by proteasome inhibitors |
EP3534965A4 (en) | 2016-11-03 | 2020-06-24 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by hdac inhibitors |
CN108779179B (en) | 2016-11-28 | 2022-02-08 | 江苏恒瑞医药股份有限公司 | CD47 antibody, antigen binding fragment thereof and medical application thereof |
JP7173971B2 (en) | 2016-12-09 | 2022-11-16 | アレクトル エルエルシー | ANTI-SIRP-α ANTIBODY AND METHOD OF USE THEREOF |
JP7179743B2 (en) | 2017-02-17 | 2022-11-29 | オーエスイー・イミュノセラピューティクス | Novel use of anti-SIRPg antibody |
WO2018175790A1 (en) | 2017-03-22 | 2018-09-27 | Arch Oncology, Inc. | Combination therapy for the treatment of solid and hematological cancers |
KR20190133198A (en) | 2017-03-27 | 2019-12-02 | 셀진 코포레이션 | Methods and Compositions for Reducing Immunogenicity |
WO2018176132A1 (en) | 2017-03-28 | 2018-10-04 | Trillium Therapeutics Inc. | Cd47 blockade therapy |
CN110650976B (en) | 2017-04-13 | 2024-04-19 | 赛罗帕私人有限公司 | Anti-SIRP alpha antibodies |
CA3063622A1 (en) | 2017-05-16 | 2018-11-22 | Synthon Biopharmaceuticals B.V. | Anti-sirp.alpha. antibodies |
WO2018236904A1 (en) | 2017-06-19 | 2018-12-27 | Surface Oncology, Inc. | Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof |
PT3642242T (en) | 2017-06-21 | 2024-04-16 | Univ Leland Stanford Junior | Dosing parameters for cd47 targeting therapies to hematologic malignancies |
WO2019023347A1 (en) | 2017-07-26 | 2019-01-31 | Forty Seven, Inc. | Anti-sirp-alpha antibodies and related methods |
CN109422811A (en) | 2017-08-29 | 2019-03-05 | 信达生物制药(苏州)有限公司 | Anti-cd 47 antibody and application thereof |
-
2020
- 2020-06-05 JP JP2021572418A patent/JP2022535286A/en active Pending
- 2020-06-05 MA MA056119A patent/MA56119A/en unknown
- 2020-06-05 EP EP20750429.1A patent/EP3980747A1/en active Pending
- 2020-06-05 CN CN202080041810.5A patent/CN114206912A/en active Pending
- 2020-06-05 WO PCT/US2020/036425 patent/WO2020247820A1/en unknown
- 2020-06-05 US US16/894,468 patent/US20200400662A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20120220049A1 (en) | Assay method and device | |
RU2010148904A (en) | ANTIBODIES TO INTERLEUKIN-1ALPHA AND METHODS OF APPLICATION | |
JPH06501555A (en) | Improvements in solid-phase binding assays | |
JP2010538623A5 (en) | ||
JP2011530514A5 (en) | ||
TWI585410B (en) | Immunochromatographic assay, immunochromatographic assay, and immunochromatographic assay kits | |
WO2018001214A1 (en) | Rapid mouse antibody subtype typing kit and preparation method therefor | |
CA2458795A1 (en) | Improved methods for determining binding affinities | |
WO2007048084A2 (en) | Forensic test for human saliva | |
JPWO2007114337A1 (en) | Immunoagglutination reagent kit and antigen measurement method | |
CN112740037A (en) | Method for measuring glycated hemoglobin [ (% ]) | |
Visentin et al. | Calibration free concentration analysis by surface plasmon resonance in a capture mode | |
EP1531332B1 (en) | Analysis and typing of monoclonal proteins by capillary electrophoresis and immunoshift | |
JPWO2020247820A5 (en) | ||
JP2009222712A (en) | Method, reagent and kit for detecting metichillin resistant staphylococcus | |
JP2016031250A (en) | Target protein measurement reagent, and measurement method using the same | |
EP2833145B1 (en) | Immunochromatographic test strip and detection method using immunochromatography for detecting target in red blood cell-containing sample | |
JP2001512574A (en) | Methods and kits for determining haptoglobin phenotype and uses thereof | |
CA2499355A1 (en) | Compositions, methods and kits for detection of an antigen on a cell and in a biological mixture | |
EP4286850A1 (en) | Immunological assay method | |
JP4783872B2 (en) | Immunoassay method | |
Thomas et al. | Specific binding and release of cells from beads using cleavable tetrameric antibody complexes | |
KR20230114327A (en) | Compositions and methods for isolating, detecting, and analyzing fetal cells | |
JP2018519525A5 (en) | ||
Strobl et al. | Easy assessment of the avidity of polyclonal allergen‐specific serum antibodies |